CA
NZ
UK
AU
IND
US
The uptick reflects a noticeable shift, as growth sources diversify away from pandemic-related products, which had previously dominated sales. The company’s proactive adjustment in its product portfolio is vital amid expectations of declining COVID-related revenues, with management raising its full-year guidance midpoint slightly. This …
Tempest Therapeutics, Inc. (NASDAQ: TPST) will see a significant change in its financial leadership with the appointment of Nicholas Rossettos as Chief Financial Officer. Rossettos is set to take over the role effective September 1, 2026, following the resignation of Justin Trojanowski, who has …
In the wake of rising layoffs, many individuals are turning to COBRA forHealth Insurancecoverage, with reports showing a notable increase in inquiries. Job losses often lead employees to seek this temporary insurance option, which allows them to continue their previous employer's health plan. The …
Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) celebrated a significant milestone on August 19, 2026, by announcing favorable topline results from their Phase 3 clinical trial for intismeran autogene. This innovative individualized neoantigen therapy outperformed Keytruda alone in terms of recurrence-free survival rates for …
Novo Nordisk has entered a significant partnership with Amazon Web Services (AWS) to enhance its drug discovery capabilities through the integration of advanced artificial intelligence and cloud computing. The initiative establishes AWS as the company’s primary cloud service provider, expanding its collaboration beyond administrative …
Oruka Therapeutics, Inc. (NASDAQ: ORKA) has appointed Todd Edwards to the position of Chief Commercial Officer, commencing his tenure on August 24, 2026. Edwards, who is 63 years old, will earn an annual base salary of $525,000. He steps into a vital role aimed …
Settlement Could Resolve Long-Standing Legal Issues
This transaction closed on August 24, 2026, and provides essential capital for the company. The funds raised significantly enhance its financial position and stockholders' equity, which is now confirmed to be above $2.5 million, effectively helping it to maintain compliance with Nasdaq's listing requirements. …
Ensysce Biosciences, Inc. (NASDAQ: ENSC) secured over $21 million in gross proceeds during the initial closing of its Series C Preferred Stock financing on August 7, 2026. This marks a significant achievement for the company, which is pursuing a total goal of approximately $43 …
Gilead Sciences, Inc. experienced a striking contrast in its second-quarter earnings report for 2026. The company generated product sales of $7.6 billion, marking a 10% increase excluding its COVID-19 therapy, Veklury. Yet, significant investments, totaling over $11 billion in R&D, culminated in one of …
Please wait processing your request...